• Medientyp: E-Artikel
  • Titel: S‐ketamine and GABA‐A‐receptor interaction in humans: an exploratory study with I‐123‐iomazenil SPECT
  • Beteiligte: Heinzel, Alexander; Steinke, Rainer; Poeppel, Thorsten Dirk; Grosser, Oliver; Bogerts, Bernhard; Otto, Hans; Northoff, Georg
  • Erschienen: Wiley, 2008
  • Erschienen in: Human Psychopharmacology: Clinical and Experimental
  • Sprache: Englisch
  • DOI: 10.1002/hup.960
  • ISSN: 1099-1077; 0885-6222
  • Schlagwörter: Pharmacology (medical) ; Psychiatry and Mental health ; Neurology (clinical) ; Neurology
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: <jats:title>Abstract</jats:title><jats:sec><jats:title>Objective</jats:title><jats:p>We aimed to probe for regional cerebral effects of S‐ketamine on <jats:italic>in vivo</jats:italic> GABA‐A‐receptor binding in healthy human subjects.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>We investigated I‐123‐iomazenil SPECT before, during and after administration of S‐ketamine in a blinded placebo‐controlled study design (<jats:italic>n</jats:italic> = 12 in both groups). Analyses of SPECT were performed with voxel‐based statistical parametric mapping (SPM), and statistical comparisons were made between the groups. We also assessed biochemical and behavioural changes during S‐ketamine infusion.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>S‐ketamine induced positive and negative symptoms measured by the Brief Psychiatric Rating scale (BPRS). It increased the cortisol and prolactin levels. Image analysis revealed significantly decreased I‐123‐iomazenil binding in bilateral dorsomedial prefrontal cortex during S‐ketamine administration when compared to placebo.</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>Our study delivers preliminary evidence for an <jats:italic>in vivo</jats:italic> interaction of S‐ketamine with GABA‐A‐receptors in human dorsomedial prefrontal cortex. Copyright © 2008 John Wiley &amp; Sons, Ltd.</jats:p></jats:sec>